Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

The full results of the ANNEXA-I trial have continued to show mixed effects of the factor Xa inhibitor reversal agent, andexanet (Andexxa/Ondexxya, AstraZeneca), in patients with intracerebral ...

Treatment with the bleeding reversal agent andexanet (Andexxa) in people with acute intracerebral hemorrhage on factor Xa inhibitors led to less expansion of hematoma volume but was associated with ...

"[...] this is the first study to address the effects of Xa-Is on composite cardiovascular events, congestive heart failure, arteriosclerotic disease, and ...

Factor Xa inhibitors used to treat and prevent thrombotic events may cause or worsen acute major bleeding. New data suggest that bleeding episodes associated with factor Xa inhibitors may be treatable ...

Acute intracerebral hemorrhage may occur in patients on factor Xa inhibitors. The efficacy and safety of the FXa inhibitor reversal agent andexanet for limiting ICH volume expansion are unknown. New ...